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OW-grade gliomas are a heterogeneous group of
brain tumors with variable biological behaviors.
Every year, 1500 new cases of LGGs are diagnosed
and the majority of these occur within the supratentorial
hemispheres in adults.4,7 Compared with patients harboring
malignant gliomas, those with LGGs are usually younger
when diagnosed. Approximately one half of patients pre-
sent with seizures and are otherwise neurologically intact.
Magnetic resonance imaging typically demonstrates a low-
signal lesion that does not enhance on T1-weighted images
with Gd and a high signal without mass effect on T2-weight-
ed images. 
The histological characteristics of LGGs are diverse, and
approximately 31.1% of these lesions consist of low-grade
astrocytomas, oligodendrogliomas, and ependymomas.
There are also LGGs of mixed histological characteristics
of which oligoastrocytoma occurs most commonly. Al-
though some LGGs such as pilocytic astrocytomas and
ependymomas show limited infiltrative growth, most of
these lesions diffusely invade brain tissue. The prognosis
and treatment for these infiltrating LGGs have been the
subject of much controversy in the literature. Patient age,
presence of neurological deficit, tumor size and extension
across the midline, and histological subtype (in particular,
the presence of an oligodendroglioma component) appear
to be the most important prognostic factors.2,17 Overall me-
dian survival in patients with infiltrative LGGs is between
3 and 9 years.17,18
Infiltrative LGGs are known to dedifferentiate to more
aggressive histological characteristics. The incidence of
malignant tumor transformation in various clinical series
has ranged from 13 to 86%.1,10,12,13,15,16 In many of these stud-
ies, however, malignant transformation is not well docu-
mented. Deficiencies in histological data from repeated sur-
geries and substantial differences in tumor grading systems
that define permissible anaplastic features for the diagnosis
of an LGG may account for the wide range of transforma-
tion rates. In addition, many of these patients received ra-
diation therapy and/or chemotherapy, which may have in-
terfered with histological interpretation and confounded the
natural progression of the LGG. 
The aim of this study was to determine the rate of and
factors influencing tumor progression as well as to analyze
malignant transformation in a well-defined cohort of adult
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Object. Progression of infiltrative low-grade gliomas (LGGs) has been reported previously. The limitations of such
studies include diverse histological grading systems, intervening therapy, and the lack of histological confirmation of
malignant tumor progression. The aim of this study was to determine tumor progression in adult patients with an ini-
tial diagnosis of infiltrative LGG who subsequently underwent a repeated operation, but no other intervening therapy.
The authors examined factors that may be associated with tumor progression.
Methods. The authors retrospectively reviewed a database of 300 patients with the initial diagnosis of LGG and who
had been treated at their institution between 1990 and 2000. One hundred four of these patients had undergone a sec-
ond surgery. Patients with infiltrative LGGs who had undergone two surgical procedures at least 3 months apart with-
out intervening therapy were selected; the authors identified 40 patients who fit these criteria. Clinical, neuroimaging,
and pathological data were centrally reviewed.
There were 29 men and 11 women in the study, whose median age was 35.5 years (range 23–48 years). At the time
of the second surgery, 50% of patients had experienced tumor progression. Patients whose tumors had progressed had
a longer median time to repeated operation (49 compared with 22.5 months). Patients who had undergone gross-total
resection, as demonstrated on postoperative magnetic resonance images, had a median time to repeated operation of
49 compared with 25 and 24 months in patients who underwent subtotal resection and biopsy, respectively (p = 0.02).
The extent of resection did not influence the likelihood of tumor progression (p ✂ 0.3).
Conclusions. Fifty percent of patients with initially diagnosed infiltrative LGGs had tumor progression at the time
of a repeated operation. A gross-total resection was associated with an increased time to repeated surgery. There was
no statistically significant effect of gross-total resection as a predictor of tumor progression. 
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patients who had undergone repeated operations without
confounding therapy by using a uniform histological grad-
ing system in the era of MR imaging.
Clinical Material and Methods 
Study Characteristics
The Neurosurgery and Neuro-Oncology database was
searched for patients treated for LGGs at the University of
California at San Francisco between 1990 and 2000; 300
such patients were identified. One hundred four patients
had undergone two operations during the course of their ill-
ness. In 11 patients diagnostic biopsy was performed less
than 3 months prior to the second (and final) operation;
these patients were excluded from further analysis. Forty
patients met all inclusion criteria and were eligible for the
study. Inclusion criteria consisted of the following: 1) pa-
tient age older than 17 years; 2) histological confirmation of
an infiltrative LGG at the initial surgery; 3) a second surgi-
cal procedure at least 3 months after the initial surgery; 4)
no intervening therapy between surgeries; 5) MR images
obtained at initial diagnosis and at the time of repeated sur-
gery; and 6) central pathological review of all specimens. 
The following information was coded for computer anal-
ysis for each patient: demographics, date of first and second
surgery, signs and symptoms at diagnosis and tumor pro-
gression, MR imaging findings prior to operation, tumor
histological characteristics at both surgeries, and location
and extent of resection. In this analysis, the definition of the
extent of resection was based on the surgeon’s operative
notes and postoperative imaging studies. Subtotal resection
was characterized as up to 90% excision and gross-total re-
section as greater than 90% removal.
This study was conducted with approval from both the
Committee on Human Research and the Institutional Re-
view Board at the University of California at San Francisco.
Neuropathological Analysis
All tumor samples obtained during the first and second
surgeries were interpreted by a team of neuropathologists at
the University of California at San Francisco. The WHO
classification system was uniformly used to identify low-
grade histological characteristics.9 To be considered WHO
Grade II, the tumor sample had no evidence of increased
mitosis, endothelial proliferation, or necrosis. 
Statistical Analysis
Because the length of follow up from the time of first sur-
gery varied, we analyzed the predictors of the likelihood
of tumor progression by using a Cox proportional-hazards
model. If data obtained during the second surgery indicated
there was no progression, the time to tumor progression was
considered to be censored. Predictors of the time to second
surgery were analyzed using the Wilcoxon rank-sum test.
Results
Patient Characteristics
There were 29 men and 11 women. Tumors were located
on the left side in 21 cases and on the right in 19. The pre-
dominantly involved cerebral lobe was the frontal in 20 pa-
tients, temporal in 11, parietal in eight, and occipital in one
patient. All biopsies were performed with the aid of image
guidance. Patient characteristics, MR imaging findings, and
tumor pathological characteristics at the time of first and
second surgeries are summarized in Table 1. Patients most
often presented with the new onset of seizures. None suf-
fered chronic epilepsy prior to diagnosis. On neuroimaging
for head trauma or migraine evaluation an incidental intra-
cranial mass was demonstrated in five patients. In only two
patients was minimal diffuse enhancement exhibited on
diagnostic MR images. Given the retrospective nature of
this study, MR imaging reports were available; initial scans
were not reviewed, however, and so tumor diameters and
volumes are unavailable in these cases. The initial patho-
logical analysis revealed 10 WHO Grade II astrocytomas,
14 Grade II oligodendrogliomas, and 11 Grade II mixed oli-
goastrocytomas. Five infiltrative LGGs could not be further
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TABLE 1
Summary of tumor characteristics and progression in 40 patients*
Tumor Grade at 1st Op
Oligo- Oligo-
Astro- astro- dendro-
cytoma cytoma glioma LGG
Variable II II II II
no. of patients 10 11 14 5
age (yrs) 
median 36.5 31 35.5 41
range 29–47 24–47 23–48 26–45
time to 2nd op (mos)
median 11.5 46 35 33
range 5–57 12–86 3–125 18–65
no. of patients w/ symptoms
before 1st op
seizure 9 5 11 3
headache 1 2 2 0
incidental finding 0 2 1 2
neurological deficit 0 2 0 0
before 2nd op
increasing seizures 6 6 5 4
increasing headaches 0 2 0 1
stable 2 2 5 0
neurological deficit 2 1 4 0
MRI results before 1st op
no enhancement 10 11 13 4
min enhancement 0 0 1 1
MRI results before 2nd op
new enhancement 3 5 6 3
no enhancement 7 6 8 2
tumor grade at 2nd op
astrocytoma
II 2 0 0 0
III 0 1 0 0
oligoastrocytoma
II 4 5 0 1
III 2 3 1 0
AA III 2 0 0 1
oligodendroglioma
II 0 0 7 1
III 0 2 4 0
GBM 0 0 2 2
tumor progression (%) 40 55 50 60
extent of resection after 1st op†
subtotal 4 5 8 2
gross total 0 5 3 2
* AA = anaplastic astrocytoma.
† All other patients underwent biopsy only.
classified despite the use of special histological stains and
central review. 
At the time of the second surgery most patients present-
ed with increasing seizures. In nine patients with stable
symptoms at second surgery tumor progression was dem-
onstrated on MR images (Table 2). In 17 patients evidence
of new enhancement was exhibited on MR images. Neuro-
imaging studies in 20 patients revealed no enhancement but
increasing abnormalities on T2-weighted images. All tumor
recurrences were local. Three patients whose residual ab-
normality had stabilized according to T2-weighted images
underwent a second surgery as part of their therapy for
medically refractory seizures. Pathological characteristics
found at the time of second surgery are shown in Table 2.
Overall, in 20 patients the tumor remained at Grade II and
in the other 20 the tumor progressed to Grade III or IV.
Thus, 50% of patients had experienced tumor progression
at the time of repeated surgery. 
A comparison of patient characteristics based on initial
low-grade tumor pathological characteristics and subse-
quent progression is summarized in Table 1. Forty percent
of astrocytomas, 55% of oligoastrocytomas, 50% of oligo-
dendrogliomas, and 60% of LGGs progressed. 
Analysis of the Results of Second Surgery
To find differences between patients whose tumors re-
mained histologically stable and those whose tumors were
upgraded, we considered several factors (Table 2). There
was a tendency toward tumor progression in patients who
were older (32 years in patients without tumor progression
compared with 42 years in patients with progression), but
this did not reach statistical significance (✂ 0.5). Four
(35%) of 13 biopsies, six (38%) of 17 subtotal resections,
and 10 (100%) of 10 gross-total resections were associated
with tumor progression. Patients who harbored tumors that
had progressed had a longer median time to second surgery
(47 months) compared with patients who harbored histo-
logically stable tumors (22.5 months). The most important
factor in determining the time to repeated operation was
the extent of initial resection. Patients who had undergone
a gross-total resection, as demonstrated on postoperative
MR images, had a median time to repeated surgery of 49
months, compared with 25 months in those who had subto-
tal resection and 24 months in those who had undergone bi-
opsy (p = 0.02, comparing gross-total resection with subto-
tal resection and biopsy). When the extent of resection as a
predictor of tumor progression was adjusted for the time
between initial and second surgery in a Cox model, there
was no indication that the extent of resection influenced
the likelihood of progression (p ✂ 0.3). New enhancement
demonstrated on MR images prior to the second surgery
was more common in patients with upgraded tumors (13
patients compared with four), but seven patients whose im-
ages revealed nonenhancing progression had tumors that
had progressed to Grade III. New enhancement on MR im-
ages had a sensitivity of 65% and a specificity of 80%. Tu-
mor progression was similar in all histological subgroups.
Discussion
Infiltrative LGGs are tumors found in young adults,
which may transform into more malignant lesions. Most in-
vestigators think that the death of patients with LGGs is
primarily due to malignant recurrence. The incidence of
malignant tumor transformation varies in published reports
and ranges from 13 to 86%.10–13,15,16,20,22,23 This large range
may be due to the use of diverse histological grading sys-
tems, intervening therapies, low rates of repeated surgeries,
and a definition of malignant transformation that was based
on an aggressive clinical course at the time of recurrence
and limited follow-up time. Many of these reports involved
patients treated during the pre–MR imaging era.
Muller, et al.,12,13 published two large reports on patients
with supratentorial recurrences of astrocytomas and oligo-
dendrogliomas. The modified Ringertz classification sys-
tem,12,13 which allowed for some mitoses, vascular changes
and minor areas of necrosis even in low-grade tumors, was
used. Many of the 137 patients with astrocytomas and the
52 patients with oligodendrogliomas had undergone inter-
vening radiation. Nevertheless, there were 47 patients with
astrocytomas and 16 patients with oligodendrogliomas who
were considered to have low-grade tumors and had under-




Patient characteristics and tumor findings at the second surgery
Tumor Grade at 2nd Op
Variable II III/IV




time to 2nd op (mos)
median 22.5 47
range 3–45 6–86




incidental finding 4 0
neurological deficit 1 0
before 2nd op
increasing seizures 11 10
increasing headaches 2 3
stable 4 5
neurological deficit 3 4
MRI results before 1st op
no enhancement 19 19
min enhancement 1 1
MRI results before 2nd op
new enhancement 4 13
no enhancement 13 7
stable 3 0
initial tumor type
astrocytoma II 6 4
oligodendroglioma II 7 7
oligoastrocytoma II 5 6
LGG 2 3
tumor type at 2nd op
astrocytoma 2 Grade II 4 Grade III
oligodendroglioma 8 Grade II 6 Grade III
oligoastrocytoma 10 Grade II 6 Grade III
GBM 0 4
extent of resection after 1st op*
subtotal 11 6
gross total 0 10
* All other patients underwent biopsy only.
gone repeated operations after clinical progression without
intervening radiation. Of the 47 astrocytomas, seven re-
mained at Grade II and 40 progressed (15 GBMs). Of the
16 oligodendrogliomas, five remained stable and 11 pro-
gressed. Excluding patients who had undergone radiation
therapy, there were malignant transformation rates of 85.1
and 69% in those harboring astrocytomas and oligoden-
drogliomas, respectively. The median age of the patients in
this study was 42 years and the median time to repeated sur-
gery was 24 months. 
Laws, et al.,10 reviewed data in 461 patients with low-
grade astrocytomas as defined by the Kernohan histological
grading system. These patients underwent surgery and radi-
ation therapy. Seventy-nine patients had recurrent tumor
documented on repeated operation or autopsy. In this series,
39 (49%) of 79 patients had tumors that progressed. 
Piepmeier16 reported one of the lowest malignant trans-
formation rates (13.3%). Sixty patients with astrocytomas,
including seven mixed and three pleomorphic xanthoastro-
cytoma, were included in this study. Fifty-one percent of
patients received radiation therapy. In eight patients a ma-
lignant change in the tumor was noted. Six patients were di-
agnosed based on biopsy results and two by computerized
tomography scanning findings. Only 14 patients had under-
gone repeated operations at the time of the report. The rate
of malignant transformation in patients who underwent a
second surgery was approximately 42.8% (six of 14 pa-
tients). 
The rate of malignant transformation in our study was
50%. This confirms that malignant progression of infiltra-
tive LGGs occurs in a significant number of patients at the
time of a second surgery. We tried to minimize the degree
of histological variability by using centralized pathological
review and a uniform grading scheme. In addition, patients
who had undergone intervening therapy with radiation ther-
apy or chemotherapy were excluded to decrease the histo-
logical artifacts that may have resembled tumor dediffer-
entiation. Limitations of this study were its retrospective
nature and the lack of a uniform follow-up evaluation be-
tween the two surgical procedures. Despite these limitations
and the fact that this was a small cohort, there are some
important implications in the fact that 50% of patients expe-
rienced tumor progression at the time of the second surgery. 
Age in this group of patients did not predict the occur-
rence of malignant transformation at the time of second sur-
gery. Patients older than 40 years of age are considered at
risk for malignant tumor transformation. The median age of
patients at the time of repeated operation in this study was
only 37.5 years. Five patients older than 40 years harbored
tumors that remained stable at the time of the repeated oper-
ation and seven patients harbored tumors that progressed. 
The influence of the extent of resection on malignant
transformation is controversial. In most studies researchers
did not document the extent of resection based on MR im-
ages obtained 24 to 72 hours postoperatively. In 1994 Berg-
er, et al.,3 used MR images and computerized tomography
scans to evaluate the effect of the extent of resection. This
study was based on 53 patients with low-grade astrocy-
tomas and mixed oligoastrocytomas. In addition to having
undergone surgery, 75% of patients received postoperative
radiation therapy. Ten of 53 patients underwent a second
surgery for recurrent tumors, three had lesions that re-
mained stable, and seven had lesions that progressed (two
anaplastic astrocytomas and five GBMs). All seven patients
with a malignant recurrence also had a preoperative tu-
mor volume of 30 cm3. Further, the recurrence rate depend-
ed on the postoperative tumor volume. A recurrence rate of
46.2% occurred in patients with postoperative tumor vol-
umes greater than 10 cm3; 14.3% of recurrences occurred in
patients with postoperative tumor volumes less than 10 cm3.
In this study all patients who had undergone 100% resec-
tions remained recurrence free during the follow-up peri-
od (mean 54 months). These patients also tended to have
smaller tumors and were younger. 
One limitation of the current study is its lack of data re-
garding the initial tumor size or volumetric analysis of re-
sidual tumor following initial resection. It may well be that
these factors influence the timing or degree of tumor pro-
gression. Pignatti, et al.,17 demonstrated that a tumor size
larger than 6 cm was an important prognostic factor for pa-
tient survival and that the influence of this factor with
respect to tumor dedifferentiation must be studied in a pro-
spective manner. The Radiation Therapy Oncology Group
study18 of good risk patients with infiltrative LGGs (age ✁
40 years and gross-total resection of tumor) who are being
followed up with neuroimaging studies but no intervening
therapy may be an ideal subset of patients to provide this
information. In our study, although 10 patients with prior
gross-total resection harbored tumors that had progressed at
the time of second surgery, the number is too small for any
conclusions regarding the effect of such resections on ma-
lignant transformation. 
The effect of therapeutic modalities such as radiation
therapy and chemotherapy on the natural progression of an
infiltrative LGG is unclear. We plan to review a similar co-
hort of matched patients harboring such tumors who had
undergone repeated operations following therapy in an at-
tempt to compare the results of frequency and timing of tu-
mor progression.
The influence of malignant transformation on patient sur-
vival is also controversial. Data from some studies have
shown that most patients die of malignant transformation.
Our data indicate that malignant changes occur most fre-
quently within the first 5 years after the initial procedure, al-
though tumor progression and histological upgrade also oc-
curred beyond 5 years. Outcome data in these patients in
terms of their survival following repeated surgery continue
to be assessed, and at the time of this report most patients
are alive. In those in whom GBM was subsequently di-
agnosed, it will be interesting to assess patient outcome
because these lesions would be considered the classic sec-
ondary glioblastoma as opposed to the de novo glioblas-
toma.9 Expected survival in patients harboring these two
types of tumors has not been described separately in studies
focused on glioblastomas. 
The implications of data in this report are extremely rel-
evant to investigators planning prospective therapeutic
studies in patients with recurrent glioma. If the initial histo-
logical subtype of a tumor is low grade and the diagnosis
of progression is based purely on clinical and radiographic
criteria, the histological diagnosis in this group could vary
from Grades II to IV, thereby making it difficult to deter-
mine the true effect of therapy on patient outcome. One can-
not assume that the grade of a recurrent infiltrative LGG has
remained stable regardless of patient age, clinical signs and
symptoms, or neuroradiographic features, thus emphasizing
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the importance of histological confirmation prior to enroll-
ment into clinical trials.
Perhaps the most relevant implication of this study is the
demonstration of heterogeneity among infiltrative LGGs
and the need for better predictors of tumor behavior and
malignant transformation other than accepted clinical and
histological factors. Molecular and cytogenetic analyses
may yield better insights into the multistep process of ma-
lignant tumor progression, especially in a unique cohort
such as in this study in which intrapatient sampling was
available at two different time points in the individual’s ill-
ness. The development of tissue arrays and patterns of gene
expression relevant to gliomagenesis can, we hope, advance
our understanding of the malignant phenotype and allow for
appropriate interventions that may delay or abrogate tumor
progression.5,6,8,14,19,21,24 We are currently assessing as many
tissue samples as possible in this cohort of patients, with
plans to evaluate at the time of initial diagnosis potential
markers that may predict tumor progression. We also plan
to look at changes that occur on a molecular and cytogenet-
ic basis during malignant transformation. 
Conclusions
Data from this study demonstrate that tumor progression
occurs in 50% of a select group of infiltrative LGGs sub-
jected to second surgeries. Patient age was not a significant
factor in predicting tumor progression in this study. Gross-
total resection without postoperative adjuvant therapy was
associated with increased time to second surgery. Future
studies ought to be directed at the molecular and cytogenet-
ic profiles of the tissue samples obtained as well as the eval-
uation of patients who underwent repeated operations fol-
lowing therapeutic intervention.
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